Immunoresolvents are endogenous lipid mediators—collectively known as Specialized pro-resolving mediators (SPMs)—that actively orchestrate the termination and resolution of acute inflammation. Biosynthesized from Omega-3 (EPA, DHA) and omega-6 (arachidonic acid) fatty acids via Lipid mediator class switching, they include four major families: Resolvins, Protectins, Maresins, and Lipoxins. Unlike classical anti-inflammatory agents that merely suppress inflammatory signals, immunoresolvents are pro-resolution molecules that actively restore tissue homeostasis.
Think of acute inflammation as a construction site after a disaster—debris everywhere, emergency crews working, alarms blaring. Anti-inflammatory drugs are like disconnecting the alarm or blocking emergency vehicles from arriving. Immunoresolvents, by contrast, are the cleanup crew foreman who actively coordinates debris removal (efferocytosis), sends home the emergency responders (stops neutrophil recruitment), inspects the site for remaining hazards (antimicrobial actions), and initiates rebuilding (tissue repair).
The construction site needs BOTH the emergency response AND the cleanup crew. Without immunoresolvents, the site stays chaotic—workers keep arriving even after the fire is out, debris piles up, and reconstruction never begins. This is chronic inflammation: not too much emergency response, but too little resolution signaling. The foreman needs specific tools (omega-3 substrates) and machinery (15-LOX, 5-LOX enzymes) to do the job. Modern diets provide neither—like hiring a cleanup crew but giving them no equipment.
Immunoresolvent biosynthesis occurs during Lipid mediator class switching, when the enzymatic machinery shifts from producing pro-inflammatory eicosanoids to generating pro-resolution lipid mediators:
Biosynthetic Pathways:
- Resolvin E-series (RvE1-3): EPA → 15-LOX → 18-HEPE → RvE1/E2/E3
- Resolvin D-series (RvD1-6): DHA → 15-LOX → 17-HpDHA → RvD1-6 series
- Protectins/Neuroprotectins: DHA → 15-LOX → 17-HpDHA → 10,17-diHDHA (PD1/NPD1)
- Maresins (MaR1-2): DHA → 12-LOX (macrophages) → 14-HpDHA → MaR1/MaR2
- Lipoxins (LXA4, LXB4): arachidonic acid → 15-LOX + 5-LOX → 15-HETE → LXA4/LXB4
- Aspirin-triggered SPMs: Acetylated COX-2 converts EPA/DHA → 15-epi-LX/Rv (15R configuration vs normal 15S)
Receptor Signaling:
Each SPM class binds specific GPCRs to trigger resolution cascades:
graph TD
RvE1[RvE1] --> ERV1[ERV1/ChemR23]
RvD1[RvD1] --> DRV1[DRV1/GPR32]
RvD2[RvD2] --> GPR18[GPR18]
LXA4[LXA4] --> ALX[ALX/FPR2]
MaR1[MaR1] --> LGR6[LGR6]
ERV1 --> StopPMN["↓ Neutrophil recruitment"]
DRV1 --> Efferocytosis["↑↑ Macrophage efferocytosis"]
GPR18 --> TregDiff["↑ Treg differentiation"]
ALX --> StopIL8["↓ IL-8, ↓ NFκB"]
LGR6 --> WoundHeal["↑ Tissue regeneration"]
StopPMN --> Resolution[Resolution Phase]
Efferocytosis --> Resolution
TregDiff --> Resolution
StopIL8 --> Resolution
WoundHeal --> Resolution
Key Molecular Actions:
-
Cessation of neutrophil infiltration: RvE1 binding to ChemR23 on endothelium blocks L-selectin/CD62L and VCAM-1-mediated rolling, reducing PMN extravasation by 40-70%
-
Enhanced efferocytosis: RvD1 (via GPR32) and MaR1 (via LGR6) activate Akt → ELMO1/Dock180/Rac1 pathway in macrophages, increasing apoptotic cell clearance 3-5 fold; also upregulates PPARγ and LXR expression
-
Inflammatory mediator suppression: ALX/FPR2 activation by LXA4 → SOCS1/SOCS3 upregulation → JAK-STAT inhibition → ↓IL-6, ↓TNF-α, ↓IL-1β production
-
Antimicrobial defense maintenance: RvD2 enhances macrophage phagocytosis of bacteria while reducing inflammatory cytokine release (uncoupling killing from collateral damage)
-
Tissue regeneration: Maresins promote epithelial cell migration via EGFR transactivation and fibroblast collagen synthesis via TGF-β1/Smad2/3
-
Pain resolution: RvE1 and RvD1 block TRPV1 and TRPA1 activation on nociceptors; reduce spinal microglial activation
Metabolic Inactivation:
SPMs are rapidly metabolized (t½ = 2-5 minutes in vivo) by:
- Eicosanoid oxidoreductase (dehydrogenation)
- β-oxidation (chain shortening)
- CYP450 ω-oxidation
This ensures resolution is time-limited and spatially controlled.
Resolution Deficit as Disease Mechanism:
Most chronic inflammatory conditions involve failed resolution rather than excessive initiation. Measuring the resolution interval (Ri) and resolution indices (Ψmax, T50, R50) identifies patients with resolution deficits:
- Ri >12 hours (normal ≤8h in acute inflammation models)
- Prolonged Ψmax (peak neutrophil infiltration) without decay
- Low plasma SPM levels (<5 ng/mL RvD1; <10 ng/mL MaR1)
Substrate Deficiency:
Modern Western diets provide omega-6:omega-3 ratios of 15-20:1 (optimal 3-4:1), starving SPM biosynthesis. The Omega-3 index (EPA+DHA in erythrocyte membranes) <4% indicates severe depletion; target >8% for adequate resolution capacity.
Genetic Polymorphisms:
- 15-LOX rs916055: Reduced enzyme activity → 30-40% lower RvD production
- ALX/FPR2 variants: Impaired LXA4 signaling in ~12% of Europeans
- 5-LOX rs2228064: Affects both leukotriene and resolvin synthesis
Clinical Applications by System:
Immune System:
Metabolic System:
- Type 2 Diabetes: Adipose tissue resolution deficit → chronic metaflammation; MaR1 improves insulin sensitivity
- NAFLD/NASH: Hepatic resolution failure drives fibrosis; RvD1 reduces stellate cell activation
Neuro System:
- Alzheimer's Disease: NPD1 deficiency in hippocampus; supplementation reduces amyloid burden and neuroinflammation
- Depression: Low plasma RvD1/RvD2 correlates with treatment resistance; SPM pathway polymorphisms predict SSRI response
Musculoskeletal:
- Osteoarthritis: Synovial resolution deficit; RvD1 injections reduce pain and cartilage degradation
- Post-exercise recovery: SPM levels predict muscle regeneration rate; supplementation accelerates satellite cell activation
Intervention Strategy (Metamodel 5 - Intervention):
- Substrate provision: EPA 2-3g/day, DHA 1-2g/day (pharmaceutical-grade omega-3)
- Enzyme cofactor support: Zinc (15-LOX cofactor), B6 (transsulfuration), magnesium (membrane stability)
- Direct SPM supplementation: RvE1 (50-100 μg), RvD1 (10-50 μg), MaR1 (20-50 μg) - emerging clinical use
- Aspirin priming: Low-dose aspirin (75-100mg) acetylates COX-2 → ATL/AT-Rv production
- Trigger removal: Address underlying inflammatory drivers (gut permeability, chronic stress, obesity) per Metamodel 2-3
Evolutionary Context:
Hunter-gatherer omega-6:omega-3 ratios (~2:1) provided abundant SPM substrates. Agricultural revolution and industrial seed oils shifted this to 15-20:1, creating evolutionary mismatch in resolution capacity—our genome expects resolution substrates that modern diets don't provide.
- Four major families: Resolvins (E-series from EPA, D-series from DHA), Protectins (DHA-derived), Maresins (macrophage-derived from DHA), Lipoxins (arachidonic acid-derived)
- Key biosynthetic enzymes: 15-LOX (rate-limiting for D-series resolvins and protectins), 5-LOX (required for lipoxins), 12-LOX (maresins), COX-2 in resolution mode (aspirin-triggered SPMs)
- Specific GPCR targets: ERV1/ChemR23 (RvE1), DRV1/GPR32 (RvD1), DRV2/GPR18 (RvD2), ALX/FPR2 (LXA4, RvD1), LGR6 (MaR1), GPR37 (NPD1)
- Efferocytosis enhancement: 3-5 fold increase in macrophage clearance of apoptotic neutrophils; critical for preventing secondary necrosis and autoantigen exposure
- Rapid metabolism: t½ = 2-5 minutes in circulation; ensures spatiotemporal control of resolution
- Clinical thresholds: Plasma RvD1 <5 ng/mL, MaR1 <10 ng/mL, LXA4 <50 pg/mL indicate resolution deficit
- Omega-3 index target: >8% (EPA+DHA in RBC membranes) required for adequate SPM substrate availability; <4% indicates severe depletion
- Resolution interval (Ri): Time from peak inflammation (Ψmax) to 50% reduction in PMNs; normal acute inflammation Ri ≤8h; chronic conditions often Ri >12-24h
- Aspirin effect: Low-dose aspirin (75-100mg) acetylates COX-2 at Ser-530 → production of 15-epi-LX and AT-resolvins with equal or greater potency than native SPMs
- Antimicrobial preservation: Unlike corticosteroids, SPMs maintain or enhance bacterial clearance while reducing inflammatory tissue damage
- Specialized pro-resolving mediators (SPMs) — synonymous term; comprehensive family name for all immunoresolvents
- Resolvins — largest SPM family; E-series (EPA-derived) and D-series (DHA-derived) with distinct receptor profiles
- Protectins — DHA-derived SPMs; neuroprotectin D1 (NPD1) critical in brain and retina
- Maresins — macrophage-derived SPMs from DHA via 12-LOX; particularly important in tissue regeneration
- Lipoxins — arachidonic acid-derived SPMs; first SPMs discovered; aspirin-triggered forms (ATL) therapeutically relevant
- Lipid mediator class switching — enzymatic transition from pro-inflammatory eicosanoid synthesis to SPM production; requires COX-2 S-nitrosylation or acetylation
- Efferocytosis — macrophage clearance of apoptotic cells; primary mechanism by which SPMs resolve inflammation
- Omega-3 — essential dietary substrate; EPA for E-series resolvins, DHA for D-series, protectins, and maresins
- EPA — eicosapentaenoic acid; 20-carbon omega-3 fatty acid; substrate for resolvin E-series
- DHA — docosahexaenoic acid; 22-carbon omega-3 fatty acid; substrate for D-series resolvins, protectins, maresins
- 15-LOX — 15-lipoxygenase; rate-limiting enzyme for D-series resolvins and protectins biosynthesis
- 5-LOX — 5-lipoxygenase; required for lipoxin synthesis and some resolvin intermediates
- COX-2 — cyclooxygenase-2; when acetylated by aspirin produces 15-epi-SPMs with potent resolution activity
- arachidonic acid — omega-6 fatty acid; substrate for lipoxins and some aspirin-triggered SPMs
- NFκB — nuclear factor kappa B; transcription factor suppressed by SPM signaling via SOCS upregulation
- IL-6 — pro-inflammatory cytokine reduced by SPM signaling; LXA4 and RvD1 decrease IL-6 production 50-70%
- TNF-α — tumor necrosis factor alpha; suppressed by ALX/FPR2 activation via lipoxins
- neutrophil — primary inflammatory cell whose recruitment is halted by resolvins via L-selectin blockade
- macrophage — central resolution effector cell; polarized toward M2-like phenotype by SPMs
- PPARγ — peroxisome proliferator-activated receptor gamma; upregulated by RvD1 to enhance efferocytosis and insulin sensitivity
- Akt — protein kinase B; activated by SPM receptor signaling to drive efferocytosis via ELMO1/Dock180/Rac1
- TRPV1 — transient receptor potential vanilloid 1; pain receptor blocked by RvE1 and RvD1
- chronic inflammation — pathological state often resulting from resolution deficit rather than excess inflammatory triggers
- metaflammation — chronic low-grade metabolic inflammation; resolution deficit in adipose tissue and liver central to pathogenesis
- rheumatoid arthritis — autoimmune disease with documented SPM deficiency in synovial fluid; therapeutic target
- Type 2 Diabetes — metabolic disease with adipose tissue resolution failure; MaR1 improves insulin sensitivity
- Alzheimer's Disease — neurodegenerative condition with hippocampal neuroprotectin D1 deficiency
- wound healing — physiological process requiring coordinated SPM signaling; maresins particularly important for tissue regeneration
- gut permeability — barrier dysfunction that triggers systemic inflammation requiring resolution mechanisms
- omega-6 to omega-3 ratio — dietary determinant of SPM substrate availability; modern ratios (15-20:1) insufficient for resolution